Association Between Hyperuricemia and All-cause Mortality in People Taken Statins: a Retrospective Cohort Study

Overview

Journal Front Pharmacol

Date 2025 Mar 7

PMID 40051566

Authors

Bin Zhu

Zijun He

Mingfen Wu

Jiping Huo

Zhigang Zhao

Wei Guo

Li Yang

Affiliations

Soon will be listed here.

Abstract

Background: Statins are one of the most widely prescribed medicines in clinical practice. Their benefits have extended beyond cardiovascular applications to reduce serum uric acid levels. This study aims to investigate the relationship of hyperuricemia with the risk of all-cause mortality among individuals taking statins.

Method: A retrospective cohort study was performed using data from the National Health and Nutrition Examination Survey (NHANES) database between 2005 and 2018. The weighted Cox proportional hazards models were used to investigate the relationship between hyperuricemia and all cause-mortality.

Results: A total of 1,958 participants were enrolled for analysis. Of them 1,429 participants were with normal uric acid levels and 529 people were with hyperuricemia. After 12 years of follow-up, there were 267 participants who died from all-cause mortality in the non-hyperuricemia group and 136 died in the hyperuricemia group. Additionally, 32.49% of participants took more than five kinds of medicines in the non-hyperuricemia group compared to 42.05% participants in the hyperuricemia group. Even after adjusting for confounding factors, we found that the serum uric acid (SUA) level was significantly correlated with all-cause mortality among statin users (HR = 1.13, 95% CI:1.02-1.24, p = 0.0161). Additionally, hyperuricemia resulted in significant increases in all-cause mortality relative to non-hyperuricemia participants in three models (HR = 1.51, 95% CI:1.16-1.96, P = 0.0023).

Conclusion: Although statins have been shown to reduce uric acid levels, hyperuricemia is still significantly associated with the all-cause mortality in people taking statins. Those taking statins and having hyperuricemia should pay special attention to their SUA level.

References

Yin Y, Zhou E, Wu J . Association between hyperuricemia and long-term mortality in patients with hypertension: results from the NHANES 2001-2018. Front Cardiovasc Med. 2024; 11:1306026. PMC: 10876877. DOI: 10.3389/fcvm.2024.1306026. View

Sorensen A, Hasselbalch H, Nielsen C, Poulsen H, Ellervik C . Statin treatment, oxidative stress and inflammation in a Danish population. Redox Biol. 2018; 21:101088. PMC: 6307042. DOI: 10.1016/j.redox.2018.101088. View

Gan T, Ye Y, Mo G, Li J . Progress of uric acid in cardiovascular disease. Cardiovasc Endocrinol Metab. 2024; 13(2):e0300. PMC: 11019825. DOI: 10.1097/XCE.0000000000000300. View

Lavie G, Hoshen M, Leibowitz M, Benis A, Akriv A, Balicer R . Statin Therapy for Primary Prevention in the Elderly and Its Association with New-Onset Diabetes, Cardiovascular Events, and All-Cause Mortality. Am J Med. 2020; 134(5):643-652. DOI: 10.1016/j.amjmed.2020.09.058. View

Leung N, Yip K, Pillinger M, Toprover M . Lowering and Raising Serum Urate Levels: Off-Label Effects of Commonly Used Medications. Mayo Clin Proc. 2022; 97(7):1345-1362. PMC: 9575594. DOI: 10.1016/j.mayocp.2022.02.027. View

Rao J, Lai R, Jiang L, Wen W, Chen H . Hyperuricaemia elevates risk of short-term readmission and mortality in patients with heart failure. Open Heart. 2024; 11(2). PMC: 11529686. DOI: 10.1136/openhrt-2024-002830. View

Wang W, Tu M, Qiu X, Tong Y, Guo X . The Interplay of Systemic Inflammation and Oxidative Stress in Connecting Perirenal Adipose Tissue to Hyperuricemia in Type 2 Diabetes Mellitus: A Mediation Analysis. J Inflamm Res. 2024; 17:11319-11329. PMC: 11668320. DOI: 10.2147/JIR.S488964. View

Han Y, Cao Y, Han X, Di H, Yin Y, Wu J . Hyperuricemia and gout increased the risk of long-term mortality in patients with heart failure: insights from the National Health and Nutrition Examination Survey. J Transl Med. 2023; 21(1):463. PMC: 10339518. DOI: 10.1186/s12967-023-04307-z. View

Derosa G, Maffioli P, Reiner Z, Simental-Mendia L, Sahebkar A . Impact of Statin Therapy on Plasma Uric Acid Concentrations: A Systematic Review and Meta-Analysis. Drugs. 2016; 76(9):947-56. DOI: 10.1007/s40265-016-0591-2. View

10.

Khatiwada N, Hong Z . Potential Benefits and Risks Associated with the Use of Statins. Pharmaceutics. 2024; 16(2). PMC: 10892755. DOI: 10.3390/pharmaceutics16020214. View

11.

Ren T, Zhou E, Wu J, Wang C, Yin Y . Systemic inflammation markers independently associated with increased mortality in individuals with hyperuricemia: Results from the NHANES prospective cohort study. Immun Inflamm Dis. 2024; 12(10):e70032. PMC: 11443515. DOI: 10.1002/iid3.70032. View

12.

Zuo T, Liu X, Jiang L, Mao S, Yin X, Guo L . Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies. BMC Cardiovasc Disord. 2016; 16(1):207. PMC: 5084405. DOI: 10.1186/s12872-016-0379-z. View

13.

Paparodis R, Bantouna D, Livadas S, Angelopoulos N . Statin therapy in primary and secondary cardiovascular disease prevention. Curr Atheroscler Rep. 2024; 27(1):21. DOI: 10.1007/s11883-024-01265-9. View

14.

Li B, Chen L, Hu X, Tan T, Yang J, Bao W . Association of Serum Uric Acid With All-Cause and Cardiovascular Mortality in Diabetes. Diabetes Care. 2022; 46(2):425-433. DOI: 10.2337/dc22-1339. View

15.

He G, Liu X, Liu L, Yu Y, Chen C, Huang J . A nonlinear association of total cholesterol with all-cause and cause-specific mortality. Nutr Metab (Lond). 2021; 18(1):25. PMC: 7945313. DOI: 10.1186/s12986-021-00548-1. View

16.

Akbari A, Razmi M, Rafiee M, Watts G, Sahebkar A . The Effect of Statin Therapy on Serum Uric Acid Levels: A Systematic Review and Meta-analysis. Curr Med Chem. 2023; 31(13):1726-1739. DOI: 10.2174/0929867330666230207124516. View

17.

Crawley W, Jungels C, Stenmark K, Fini M . U-shaped association of uric acid to overall-cause mortality and its impact on clinical management of hyperuricemia. Redox Biol. 2022; 51:102271. PMC: 8889273. DOI: 10.1016/j.redox.2022.102271. View

18.

Mangione C, Barry M, Nicholson W, Cabana M, Chelmow D, Coker T . Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2022; 328(8):746-753. DOI: 10.1001/jama.2022.13044. View

19.

Athyros V, Elisaf M, Papageorgiou A, Symeonidis A, Pehlivanidis A, Bouloukos V . Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis. 2004; 43(4):589-99. DOI: 10.1053/j.ajkd.2003.12.023. View

20.

Keller S, Rai S, Lu N, Oza A, Jorge A, Zhang Y . Statin use and mortality in gout: A general population-based cohort study. Semin Arthritis Rheum. 2018; 48(3):449-455. DOI: 10.1016/j.semarthrit.2018.03.007. View